Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.
作者信息
Stessman H A F, Mansoor A, Zhan F, Janz S, Linden M A, Baughn L B, Van Ness B
机构信息
Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA.
出版信息
Leukemia. 2013 Oct;27(10):2075-7. doi: 10.1038/leu.2013.148. Epub 2013 May 14.
Abstract
摘要
相似文献
1
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.在骨髓瘤小鼠模型中，CXCR4表达降低与髓外疾病相关，并预示接受硼替佐米治疗的多发性骨髓瘤患者生存期较差。
Leukemia. 2013 Oct;27(10):2075-7. doi: 10.1038/leu.2013.148. Epub 2013 May 14.
2
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.髓系肉瘤作为慢性粒细胞白血病的初始表现，酪氨酸激酶抑制剂时代的骨髓慢性期：11例报告
Am J Hematol. 2015 Aug;90(8):E146-8. doi: 10.1002/ajh.24045. Epub 2015 May 28.
3
Bortezomib increases survival of patients with relapsed multiple myeloma.硼替佐米可提高复发型多发性骨髓瘤患者的生存率。
Health News. 2005 Sep;11(9):9.
4
RAS mutation status and bortezomib therapy for relapsed multiple myeloma.RAS突变状态与硼替佐米治疗复发多发性骨髓瘤
Br J Haematol. 2015 Jun;169(6):905-8. doi: 10.1111/bjh.13258. Epub 2015 Jan 12.
5
Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.细胞周期蛋白依赖性激酶5（cdk5）的表达水平可预测复发多发性骨髓瘤患者的生存率。
Cell Cycle. 2012 Nov 1;11(21):4093-5. doi: 10.4161/cc.21886. Epub 2012 Sep 17.
6
Proteasome inhibitor for treatment of multiple myeloma.用于治疗多发性骨髓瘤的蛋白酶体抑制剂。
Lancet Oncol. 2005 Aug;6(8):546. doi: 10.1016/s1470-2045(05)70264-3.
7
Extramedullary involvement: an emerging problem in multiple myeloma.髓外浸润：多发性骨髓瘤中一个新出现的问题。
Clin Adv Hematol Oncol. 2012 Apr;10(4):268-9.
8
Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.3例伴有髓外肿块的硼替佐米耐药性多发性骨髓瘤
Tokai J Exp Clin Med. 2010 Apr 20;35(1):17-20.
9
Bortezomib in multiple myeloma.硼替佐米用于多发性骨髓瘤治疗
N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8. doi: 10.1056/NEJMc051943.
10
Bortezomib in multiple myeloma.硼替佐米用于治疗多发性骨髓瘤。
N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8.
引用本文的文献
1
A review on pathobiology of circulating tumour plasma cells: The sine qua non of poor prognosis in plasma cell neoplasms.循环肿瘤浆细胞的病理生物学综述：浆细胞肿瘤预后不良的必要条件。
Oncol Res. 2025 Apr 18;33(5):1055-1068. doi: 10.32604/or.2024.055154. eCollection 2025.
2
Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.多发性骨髓瘤获得硼替佐米耐药：从机制到策略。
Curr Treat Options Oncol. 2024 Nov;25(11):1354-1365. doi: 10.1007/s11864-024-01273-6. Epub 2024 Oct 21.
3
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.好警察，坏警察：多发性骨髓瘤的免疫景观剖析。
Biomolecules. 2023 Nov 7;13(11):1629. doi: 10.3390/biom13111629.
4
CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.CXCL12-CXCR4/CXCR7 轴在癌症中的作用：从机制到临床应用。
Int J Biol Sci. 2023 Jun 26;19(11):3341-3359. doi: 10.7150/ijbs.82317. eCollection 2023.
5
Ga-Pentixafor PET/CT May Fail to Detect Recurrent Multiple Myeloma with Extramedullary Disease.镓-喷替沙氟正电子发射断层扫描/计算机断层扫描（Ga-Pentixafor PET/CT）可能无法检测出伴有髓外病变的复发性多发性骨髓瘤。
Diagnostics (Basel). 2023 Feb 24;13(5):871. doi: 10.3390/diagnostics13050871.
6
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma.自噬和细胞凋亡：多发性骨髓瘤治疗和耐药性的当前挑战。
Int J Mol Sci. 2022 Dec 30;24(1):644. doi: 10.3390/ijms24010644.
7
Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma.染色质重塑与多发性骨髓瘤肿瘤微环境的分子串扰。
Curr Oncol. 2022 Dec 5;29(12):9535-9549. doi: 10.3390/curroncol29120749.
8
Solitary Extramedullary Plasmacytoma of the Larynx and Secondary Laryngeal Involvement in Plasma Cell Myeloma: Single-Centre Retrospective Analysis and Systematic Literature Review.喉孤立性髓外浆细胞瘤及浆细胞骨髓瘤继发喉受累：单中心回顾性分析与系统文献综述
J Clin Med. 2022 Jul 28;11(15):4390. doi: 10.3390/jcm11154390.
9
Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease.肿瘤微环境对多发性骨髓瘤播散及髓外疾病的分子影响
Front Oncol. 2022 Jul 1;12:941437. doi: 10.3389/fonc.2022.941437. eCollection 2022.
10
Adhesion molecules in multiple myeloma oncogenesis and targeted therapy.黏附分子在多发性骨髓瘤发生发展及靶向治疗中的作用
Int J Hematol Oncol. 2022 Apr 26;11(2):IJH39. doi: 10.2217/ijh-2021-0017. eCollection 2022 Apr.
本文引用的文献
1
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.对硼替佐米耐药进行分析鉴定了小鼠骨髓瘤模型中的二线治疗药物。
Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.
2
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?多发性骨髓瘤的连续 Total Therapy 试验改善了长期结果：患者现在是否被治愈了？
Leukemia. 2013 Jan;27(1):226-32. doi: 10.1038/leu.2012.160. Epub 2012 Jun 18.
3
Factors influencing the abundance of the side population in a human myeloma cell line.影响人骨髓瘤细胞系中侧群细胞丰度的因素。
Bone Marrow Res. 2011;2011:524845. doi: 10.1155/2011/524845. Epub 2011 Sep 22.
4
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.循环血浆细胞可预测复发或难治性多发性骨髓瘤的结局。
Leuk Lymphoma. 2012 Apr;53(4):641-7. doi: 10.3109/10428194.2011.627481. Epub 2011 Dec 5.
5
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.硼替佐米测试剂量的药物基因组学鉴定出蛋白酶体基因的过度表达，尤其是 PSMD4，作为在接受 Total Therapy 3 治疗的骨髓瘤中的新型高危特征。
Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.
6
Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.3例伴有髓外肿块的硼替佐米耐药性多发性骨髓瘤
Tokai J Exp Clin Med. 2010 Apr 20;35(1):17-20.
7
Proteasome inhibitors in the treatment of multiple myeloma.蛋白酶体抑制剂在多发性骨髓瘤治疗中的应用
Leukemia. 2009 Nov;23(11):1964-79. doi: 10.1038/leu.2009.173. Epub 2009 Sep 10.
8
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.CXCR4抑制剂AMD3100破坏多发性骨髓瘤细胞与骨髓微环境之间的相互作用，并增强它们对治疗的敏感性。
Blood. 2009 Apr 30;113(18):4341-51. doi: 10.1182/blood-2008-10-186668. Epub 2009 Jan 12.
9
A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.浆细胞恶性肿瘤的转基因小鼠模型表现出与人类多发性骨髓瘤相似的表型、细胞遗传学和基因表达异质性。
Cancer Res. 2007 May 1;67(9):4069-78. doi: 10.1158/0008-5472.CAN-06-3699.
10
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.蛋白酶体抑制剂硼替佐米的临床试验中的基因表达谱分析及其与结果的相关性。
Blood. 2007 Apr 15;109(8):3177-88. doi: 10.1182/blood-2006-09-044974. Epub 2006 Dec 21.
Zotero 插件